Information on suspected side effects of nationally authorised medicines now available through a single website
LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages 12-17
US HER2-Positive Breast Cancer Treatment Market to More than Treble in Value by 2023, says GlobalData
AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®
Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
Legal Settlement, Data Presentation, Welfare Initiatives, Acquisition Talks, and Study Results - Research Reports on Shire, Merck, Medtronic, Salix and Johnson & Johnson
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 1, 2014
ABBOTT PARK, Ill., Oct.
Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio
THOUSAND OAKS, Calif.